Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPBOETTIGER, David C.ESCUDER, Maria MercedesLAW, Matthew G.VELOSO, ValdileaSOUZA, Rosa A.IKEDA, Maria L. R.ALENCASTRO, Paulo R. deTUPINAMBAS, UnaiBRITES, CarlosGRINSZTEJN, BeatrizGGOMES, Jackeline O.RIBEIRO, SayonaraMCGOWAN, Catherine C.JAYATHILAKE, KaruCASTILHO, Jessica L.GRANGEIRO, Alexandre2020-08-202020-08-202020TROPICAL MEDICINE & INTERNATIONAL HEALTH, v.25, n.7, p.886-896, 20201360-2276https://observatorio.fm.usp.br/handle/OPI/37058Objectives There is a paucity of data on cardiovascular disease (CVD) among people living with HIV (PLHIV) in resource-limited countries. We assessed factors associated with CVD and the impact of prevalent CVD on all-cause mortality in PLHIV on antiretroviral therapy in Brazil. Methods Competing risk regression to assess factors associated with CVD and all-cause mortality in the HIV-Brazil Cohort Study between 2003 and 2014. Results Among 5614 patients, the rate of CVD was 3.5 (95% confidence interval [95% CI] 2.9-4.3) per 1000 person-years. CVD was associated with older age (adjusted hazard ratio [aHR] 6.4 for >= 55 years vs. <35 years, 95% CI: 2.5-16.3, P < 0.01), black race (aHR 1.8 vs. white race, 95% CI: 1.0-3.1, P = 0.04), past CVD (aHR 3.0 vs. no past CVD, 95% CI: 1.4-6.2, P < 0.01), hypertension (aHR 1.8 vs. no hypertension, 95% CI: 1.0-3.1, P = 0.04), high-grade dyslipidemia (aHR 9.3 vs. no high-grade dyslipidemia, 95% CI: 6.0-14.6, P < 0.01), ever smoking (aHR 2.4 vs. never, 95% CI: 1.2-5.0, P = 0.02) and low nadir CD4 cell count (aHR 1.8 for 100-250 cells/mm(3) vs. >250 cells/mm(3), 95% CI: 1.0-3.2, P = 0.05). The rate of death was 16.6 (95% CI: 15.1-18.3) per 1000 person-years. Death was strongly associated with having had a past CVD event (aHR 1.7 vs. no past CVD event, 95% CI: 1.1-2.7, P = 0.01). Conclusions Traditional and HIV-specific factors associated with CVD among PLHIV in Brazil are similar to those identified among PLHIV in high-income countries. PLHIV in Brazil with a history of CVD have a high risk of death. CVD care and treatment remain priorities for PLHIV in Brazil as this population ages and antiretroviral therapy use expands.engrestrictedAccessHIVcardiovascular diseasemortalityBrazilantiretroviral therapyacute myocardial-infarctionlong-term survivalnational-health surveyabacavir useantiretroviral therapiesincreased riskpopulationmortalityeventsindividualsarticleCopyright WILEY10.1111/tmi.13405Public, Environmental & Occupational HealthTropical Medicine1365-3156